PI Industries Limited — Investor Meet, 26-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

PI Industries navigated a challenging AgChem market, reporting FY26 revenue of ₹67,137 Cr with 25% EBITDA margin. Q4 revenue was ₹15,652 Cr, maintaining a 58% gross margin. Pharma grew 40% and Biologicals over 20%+. FY27 outlook projects positive growth from H2 export recovery, new product launches, and scaling diverse segments. PI is shifting to a global innovator mindset: launching its first NCE, Pioxaniliprole; advancing in Electronic Chemicals ($100M target with ₹500 Cr capex); and expanding Pharma CRDMO. Capacity utilization stands at 80%. Management remains confident in long-term strategic investments despite market volatility.